- Conditions
- Alzheimer Disease
- Interventions
- Placebo oral tablet, Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Surprise, Arizona • Miami, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 662
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer Disease
- Interventions
- Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
- Radiation · Diagnostic Test · Behavioral + 1 more
- Lead sponsor
- Samus Therapeutics, Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- Placebo, Candesartan
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer Disease, HIV
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlestown, Massachusetts
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
- Interventions
- Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
- Drug · Dietary Supplement
- Lead sponsor
- Michal Schnaider Beeri, Ph.D.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg
- Drug
- Lead sponsor
- GemVax & Kael
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more
- Conditions
- Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
- Interventions
- Juice Plus+
- Dietary Supplement
- Lead sponsor
- University of Alabama, Tuscaloosa
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Tuscaloosa, Alabama
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Placebo, Eligard 22.5Mg Suspension for Injection
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years to 120 Years · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Boca Raton, Florida • New York, New York • Madison, Wisconsin
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
- Interventions
- Not listed
- Lead sponsor
- Exonhit
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 3
- States / cities
- Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
- Conditions
- Alzheimer Disease
- Interventions
- GV-971, Placebo
- Drug
- Lead sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 2,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 67
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 57 more
- Conditions
- Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
- Interventions
- AZD3293, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Alzheimer's Disease
- Interventions
- Memantine, Placebo
- Drug
- Lead sponsor
- Florida Atlantic University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- Audio speech recording
- Other
- Lead sponsor
- East Tennessee State University
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Johnson City, Tennessee
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Centella asiatica product, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
- Interventions
- Tailored Lighting Intervention
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- BMS-241027, Placebo matching BMS-241027
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Anaheim, California • Long Beach, California • San Francisco, California + 11 more
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 98 more
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Lumbar puncture, Blood draw, Magnetic Resonance Imaging (MRI)
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer's Disease
- Interventions
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 40 Years to 64 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 18
- States / cities
- Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Interventions
- PrecivityAD blood test
- Other
- Lead sponsor
- C2N Diagnostics
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild, Dementia Moderate, Dementia Alzheimers, Dementia of Alzheimer Type, AD
- Interventions
- Sensory Stimulation System (GS120) - Active
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 92 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Anaheim, California + 48 more